Post

Beyond knee osteoarthritis: GID explores cellular medicine to potentially treat dermal, organ and more musculoskeletal diseases

From the bark of the willow tree 3,500 years ago that Egyptians and Sumerians popularized for pain relief, medicine is one industry that can be counted on for constant innovation...

Learn More

Post

GID BIO’s results in FDA-approved, multi-site, randomized, placebo-controlled Phase IIb clinical trial support an evidence-based, data-driven approach to treat pain-management caused by osteoarthritis of the knee

While minimally invasive treatments transformed cardiology decades ago, advancements in orthopedic medicine are introducing potential alternatives to traditional surgery by applying cellular medicine therapies. GID BIO is focused on using...

Learn More

Post

GID BIO, a cellular medicine company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system

AMA grants two Category III CPT® codes, paving the way for reimbursement strategies   GID BIO’s unique autologous cellular implant derived from adipose tissue is produced with its SVF-2 device...

Learn More

Post

Initial safety and feasibility of cellular medicine therapy

Companies and clinics tout the promise of cellular medicine (usually as a "stem cell therapy") backed by little more than anecdotal evidence and the hypothetical possibility of efficacy. When we...

Learn More